Is MariTide Approved? Status, FDA Path, and What Comes Next (2026)
No. MariTide is still in Phase 3. It has real late-stage importance, but it is not yet an FDA-approved broad obesity product.
Current stage
Phase 3
Approval read
Not approved in the US for broad obesity use.
Likely window
2027 to 2028 if Amgen converts the mechanism into a clean filing story.
Next step
Complete registrational data and prove the differentiated mechanism translates into an approvable, sellable product.
Direct answer
No. MariTide is still in Phase 3. It has real late-stage importance, but it is not yet an FDA-approved broad obesity product.
Status facts for search and AI answers
What this MariTide (maridebart cafraglutide) status page answers
Compound
MariTide (maridebart cafraglutide)
MariTide (maridebart cafraglutide) is tracked as a GLP-1 agonist + GIP antagonist program from Amgen.
Approval read
Not approved in the US for broad obesity use.
No. MariTide is still in Phase 3. It has real late-stage importance, but it is not yet an FDA-approved broad obesity product.
Likely window
2027 to 2028 if Amgen converts the mechanism into a clean filing story.
The likely window is a FormBlends tracking read, not a guarantee of patient access.
Next step
Complete registrational data and prove the differentiated mechanism translates into an approvable, sellable product.
This is the milestone most likely to change the page's answer.
Decision path
What does MariTide (maridebart cafraglutide)'s status mean for access?
MariTide (maridebart cafraglutide)'s approval status should be read as a regulatory signal, not a shortcut to buying or prescribing. The useful decision is whether this is approved, decision-stage, investigational, or simply worth monitoring.
- Compound
- MariTide (maridebart cafraglutide)
- Stage
- Phase 3
- Approval read
- Not approved in the US for broad obesity use.
- Window
- 2027 to 2028 if Amgen converts the mechanism into a clean filing story.
Step 1
Classify availability
Phase 3 Amgen asset with a more unconventional GLP-1 plus GIP-antagonist story.
Read compound pageStep 2
Watch required milestone
Complete registrational data and prove the differentiated mechanism translates into an approvable, sellable product.
Open pipeline trackerStep 3
Use current-care rules
If you need care now, separate trial-stage news from provider-reviewed GLP-1 options that can actually be prescribed.
Compare care routesWhat the status means now
Phase 3 Amgen asset with a more unconventional GLP-1 plus GIP-antagonist story.
MariTide matters because it is one of the few late-stage obesity assets that does not read like a routine copy of the current incretin leaders.
What needs to happen next
Complete registrational data and prove the differentiated mechanism translates into an approvable, sellable product.
What FormBlends is watching
- Whether the mechanism stays intellectually interesting and commercially plausible at the same time
- How Amgen frames dosing, tolerability, and differentiation
- Whether prescribers see it as innovative or just harder to explain
What could delay the timeline
- A complicated mechanism story that slows commercial adoption
- Any late-stage data inconsistency
- Pressure from simpler, more intuitive competitors